Hormone therapy commonly is given as a targeted treatment for women whose cancer cells carry receptors for estrogen. But the therapy only works for about half of all patients. Until now, there hasn't been a good way to reliably ...
Feb 2, 2021
0
42
(HealthDay)—Some women aged 40 to 49 years with estrogen receptor-positive breast cancer who undergo chemotherapy-induced amenorrhea regain ovarian function with letrozole, according to a study published online Feb. 16 ...
Feb 18, 2016
0
0
(HealthDay)—Use of an aromatase inhibitor in combination with growth hormone seems effective for optimizing height in 11β-hydroxylase-deficient congenital adrenal hyperplasia (CAH), according to a case report published ...
Jan 27, 2017
0
1
Although oral hormonal therapy is known to substantially reduce breast cancer recurrence in women with hormone receptor–positive tumors, about one-half of patients fail to take their medications as directed. A study by ...
Oct 28, 2014
0
0
Neoadjuvant endocrine therapy - designed to reduce the size of breast tumors before surgical removal - appears to be as effective as neoadjuvant chemotherapy for patients with localized, estrogen-receptor (ER)-positive breast ...
Nov 9, 2016
0
4
(HealthDay)—U.S. Food and Drug Administration approval of Ibrance (palbociclib) capsules has been widened to include men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic ...
Apr 6, 2019
0
3
Many breast cancer survivors take a hormonal drug after cancer treatment to stave off a recurrence, but new research suggests thesedrugs may be less effective in women who are obese.
Oct 18, 2023
0
1
Tart cherry reduces the musculoskeletal effects of aromatase inhibitors in patients with non-metastatic breast cancer, according to new findings from a clinical trial by researchers at Marshall University Joan C. Edwards ...
Jun 10, 2019
0
0
While aromatase inhibitors (AIs) are a preferred therapy for postmenopausal women who have hormone receptor-positive early-stage breast cancer, the vaginal dryness and decreased sex drive that may result can lead to poor ...
Nov 10, 2016
0
0
(HealthDay)—The U.S. Food and Drug Administration has approved ribociclib (Kisqali) in combination with an aromatase inhibitor (AI) as an initial endocrine-based therapy for the treatment of pre/perimenopausal or postmenopausal ...
Jul 24, 2018
0
2
